Hamburg, October 2018 — “Today’s cell culture requires more than technical solutions for optimized growth conditions and efficient contamination prevention,” says Eppendorf´s Business Manager for cell culture products Dr. Patrik Ferreira. “For several years, customers involved in Eppendorf´s development process have reported an increasing demand for devices that provide flexibility, support with increasing documentation demands and use natural resources sustainably. We also noticed more questions regarding a future ´connected lab´ environment during customer contacts in the last two years.” [Read more…]
CHAMP Private Equity Acquires Cell Care, Australia’s Largest Cord Blood Bank
CHAMP Private Equity is acquiring Cell Care, the largest cord blood bank within Australia, according to news released October 10, 2018, by the Australian Financial Review (AFR). According to AFR, “It is understood CHAMP will take a controlling stake in the business, while some of the vending shareholders will retain a minority shareholding.”
The transaction has important implications for the global stem cell banking marketplace, because the AFR estimates the deal to have a price tag of more than $100 million.
With this price tag, Cell Care will be well capitalized to continue its research into therapeutic applications of cord blood and tissue stem cells and may be positioned to expand into new markets beyond Australia and Canada.
[Read more…]
L7 Informatics Releases L7 Enterprise Science Platform 2.0 with Pre-Built Microsoft Genomics Integration
L7 ESP v.2.0 expands platform functionality to support complex “bench-to-bedside” life science industry and regulatory requirements
AUSTIN, Texas, Oct. 10, 2018 — L7 Informatics, Inc., formerly Lab7 Systems, a leader in informatics solutions and services for data intensive scientific applications and personalized medicine, is pleased to announce today the release of Enterprise Science Platform 2.0 (ESP) with a validated pre-built Microsoft Azure connector to the Microsoft Genomics service on the Azure cloud. [Read more…]
UniCAR Therapy and Terumo BCT Collaborate to Advance CAR T-Cell Therapies and Create a Shanghai, China Center of Excellence
LAKEWOOD, Colo., Oct. 09, 2018 — Shanghai UniCAR-Therapy Bio-Medicine Technology Co. chose Terumo BCT and its cell expansion devices to automate its cell therapy manufacturing process for chimeric antigen receptor (CAR) T-cell therapies. Privately held, UniCAR will open their Center of Excellence for Terumo BCT’s technologies in Shanghai in November.
Terumo BCT is a global leader in blood component, therapeutic apheresis and cellular therapy technologies. The company provides flexible solutions for CAR T-cell developers and manufacturers, including the Quantum® Cell Expansion System, in use at UniCAR today. [Read more…]
Gradalis® implements L7 Informatics’ Enterprise Science Platform as part of initiating their Phase 3 Study of Vigil™ in Ewing’s sarcoma
Gradalis deploys L7’s Enterprise Science Platform for next-generation life science companies in record time to support mission-critical immunotherapy manufacturing and clinical trial processes.
DALLAS, October 3, 2018 – Gradalis, Inc., a Dallas-based, clinical-stage, vertically-integrated immunotherapy company, announced today it has successfully implemented and launched L7’s Enterprise Science Platform (“ESP”). L7 Informatics, Inc., is the leading software and analytics company for life science research and manufacturing companies.
Gradalis recently upgraded its Carrollton, TX manufacturing facility to support the launch of a Phase 3 registration trial of Vigil in Ewing’s sarcoma. Gradalis’ vertically integrated research, clinical and manufacturing business model creates complex master batch record (“MBR”) requirements that few technology providers can support. [Read more…]
- « Previous Page
- 1
- …
- 219
- 220
- 221
- 222
- 223
- …
- 334
- Next Page »